(ii) The conserved upregulation of TAM-promoting genes (e.g., Arg1, Mrc1 and F13a1) across tumour types suggests that SFV-based therapies could have broader applicability in reprogramming TAMs in other malignancies, such as glioblastoma or lung cancer. The gene discussed is MRC1; the disease is neoplasm.